GlassScriptPhysician profile
Asa D Morton
NPI 1780669283
$12,063.48
in general payments reported to CMS, 2019-2025
14 companies · $952 in 2025
The $952 reported for 2025 was more than what 77% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.69 · 2020: $2,106 · 2021: $5,458 · 2022: $968 · 2023: $1,115 · 2024: $1,412 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,889 · Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,889.05 |
| Food and Beverage | $1,589.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $5,408.61 | 2019-2023 | Tepezza |
| Allergan, INC. | $2,774.04 | 2019-2023 | |
| Abbvie INC. | $1,821.23 | 2023-2025 | |
| Biotissue Holdings INC. | $986.14 | 2020 | |
| Amgen INC. | $444.32 | 2024-2025 | Tepezza |
| Argenx US, INC. | $198.09 | 2024-2025 | |
| Sight Sciences, INC. | $162.03 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $115.72 | 2024-2025 | Clareon Panoptix Pro, Clareon |
| Tarsus Pharmaceuticals, INC. | $39.74 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $32.95 | 2022-2025 | Xiidra, Miebo |
| Si-Bone, INC. | $25.99 | 2023 | |
| Oyster Point Pharma, INC. | $22.12 | 2024 | Ryzumvi, Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.22 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asa Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.